Skip to main content

Table 1 Patient baseline characteristics

From: Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Patient baseline characteristics

N (%) unless otherwise indicated

QoL analysis population (N = 80)

Male

50 (62.5)

Mean age (SD), range

63.7 (9.4), 40.4 to 85.9

Race

 White

57 (71)

 Black

8 (10)

 Other

11 (14)

 Missing

4 (5)

ECOG performance status

 0

25 (31)

 1

45 (56)

 2

7 (9)

 Missing

3 (4)

R-ISS

 1

16 (20)

 2

49 (61)

 3

14 (18)

 Missing

1 (1)

High-risk cytogenetic abnormalities (any of del(17p)/p53, t(14;16), t(4;14), or 1q21)

40 (50)

Mean number of previous regimens (SD), range

7.9 (3.1), 3 to 18

Mean years since diagnosis (SD), range

7.6 (3.4), 1.2 to 18.6

  1. QoL quality of life, ECOG Eastern Cooperative Oncology Group, R-ISS Revised International Staging System, SD standard deviation